Primary Outcome (Cirrhosis Regression): 16% (176/1,135) of patients showed cirrhosis regression (≥1-stage improvement in MASH CRN fibrosis stage). - Regression associated with 6-fold lower risk of liver-related events (HR 0.16; 95% CI 0.04–0.65). Secondary Outcomes:  Improvements in non-invasive tests (NITs): ELF score, liver stiffness by VCTE, hepatic collagen, and α-SMA expression. Reduction in HVPG (portal pressure) in regressors. The gene discussed is ACTA1; the disease is fibrosis.